Thank you for Subscribing to Life Science Review Weekly Brief
×
Life Science Review Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review
Weekly Brief
Weekly Brief
Thursday, May 12,2022
Feature of the Week
Dr. Alita Miller, Vice President, Microbiology, discussed the characterization of Acinetobacter baumannii-calcoaceticus
Read more ‣
The technological advancement in the biotechnology sector has reached a dizzying milestone in recent years. Rapid advances in this sector, ranging from biosensors to 3D bioprinting and gene editing to VR and AR
Read more ‣
Genome editing can help boost a wide variety of crops that can resist heat, floods, salinity, drought, and extreme cold.
Read more ‣
Industry Contributors
By William Leonard, ScD, Chief Information Officer, MPI Research
By
We are entering a time of dramatic transformation within medical care with a focus on technology. Every clinician I speak with expresses elevating needs and expectations for how technology will support them in care delivery.
Read more ‣
By Derya DİLEK KANÇAĞI, PhD, Laboratory Manager, Acıbadem Labcell Cellular Therapy Center
Cancer disease, which is increasing in society today, is a great concern.... Read more ‣
By Duncan Turner, General Partner, SOSV, Managing Director, HAX
The last few months have created unimaginable changes in our world. HAX, with our largest hub located... Read more ‣
Featured Vendors
By Mary Gardner, Founder and CEO
In 2016, Mary Gardner, the Founder and CEO,laid the foundation of DelNova. It is the only company in the industry that is developing a feasible solution, ReViVox™, to address botulinum toxin type A complications following aesthetic and medical... Read more ‣
By Dr. Qingxi (Charles) Wang, Chairman
AlaMab Therapeutics has emerged as a pioneer in developing novel, first-in-class antibody drugs. The company devotes a significant amount of time in educating the regulatory agency and their present and potential investors about their drug target.... Read more ‣
By Joe Eazor, President and CEO
Led by science and technology thought leaders,
visionaries, and master clinical trial management
experts, the company diligently supports regulatory
compliance across 120 countries Read more ‣
